- California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed
- Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers
- GEDI Cube is strengthening its platform’s potential by joining with the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists
- The companies hope to detect pancreatic tumors at early stages when they can be more effectively treated, using predictive modeling to analyze patients’ health profiles and potential responsiveness to therapeutic efforts
Pre-clinical biotechnology innovator Renovaro BioSciences (NASDAQ: RENB) is seeking solutions for hard-to-treat cancers and other illnesses through the use of a proprietary cell and gene solution designed to promote immune system response.
The company has demonstrated the potential of its novel technology against solid tumors in humanized mouse models that demonstrated significant pancreatic tumor size and weight reduction. Renovaro has applied for Investigational New Drug (“IND”) status that would facilitate shipping the company’s experimental therapies across state lines for use in clinical trials as it focuses on potential solutions for pancreatic cancer.
Renovaro further enhanced its opportunities for developing cancer-fighting solutions recently when it announced intent to join forces with GEDI Cube Intl Ltd. — a cutting edge health company that has developed an artificial intelligence / machine learning (AI/ML) platform expected to improve the early detection of difficult cancers at a stage when treatments may be more effective. The move is expected to greatly enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.
“Our advanced cell, gene, and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms,” Renovaro CEO Dr. Mark Dybul stated (https://ibn.fm/3XHgP). “I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”
GEDI Cube’s AI/ML platform uses a data-driven approach to detecting tumors and developing a predictive model of patients’ susceptibility to various cancers. The platform’s data is multi-omic, meaning data sets from different “omic groups” such as genomics, proteomics, transcriptomics, epigenomics, and microbiomics, are combined during analysis to develop a more thorough analysis of patients’ health conditions, since the varied omic processes influence and regulate each other (https://ibn.fm/3Nydz).
On Aug. 30, GEDI Cube announced it will be getting support for its multi-omics research from the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources and venture capitalists (https://ibn.fm/jvHP4).
NVIDIA’s infrastructure will use the Medical Imaging Open Network for Artificial Intelligence (“MONAI”) in an upcoming clinical trial designed to recognize tumors and build a predictive model based on their size and type, using GEDI Cube’s multi-omic platform in a multi-modal combination to “help provide important information for fighting cancers … that nearly always present in late stages and have predominately poor outcomes,” the news release states.
“This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage,” GEDiCube CEO Craig Rhodes stated. “(Combining) NVIDIA’s advanced medical imaging capabilities with GEDiCube’s existing multi-omic AI system will help create an algorithm that pulls from both the imaging and omic modals. This will help our scientists understand the radiology and pathology imaging data alongside multi-omic data, thus enabling a better analysis of cancer.”
For more information, visit the company’s website at www.EnochianBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
TinyGems is powered by IBN